An international team of experts has recommended that people with Parkinson’s disease and their caregivers receive vaccines for COVID-19. The recommendations were published in the Journal of Parkinson’s Disease, in a paper titled, “COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the…
News
Practicing golf may have more benefits than tai chi for improving mobility and balance in people with Parkinson’s disease, simply because it might be more enjoyable, a small study reports. The study “Feasibility and Tolerability Randomized Clinical Trial of Golf Versus Tai Chi for People with Moderate Parkinson’s…
Sesaminol, a waste product of sesame oil production with antioxidant properties that might protect nerve cells, was found to prevent some symptoms of Parkinson’s disease in a mouse model in a recent study. Treated mice, its researchers reported, showed better balance and fewer gastrointestinal issues than mice in this…
People with Parkinson’s disease experience more stress than those without this disease, and high stress levels associate with a worsening of symptoms, research based on a patient survey reported. Mindfulness, a practice of maintaining a heightened state of awareness of thoughts and feelings, may help to lower stress…
A $1-million grant has made it possible for the University of Miami Miller School of Medicine to be added to the PD GENEration study, a nationwide initiative seeking to increase the availability of genetic counseling for people with Parkinson’s disease in the U.S. “We are truly grateful for the…
A recent survey about medical cannabis use by Parkinson’s disease (PD) patients in the U.S. found one-quarter of its more than 1,000 respondents had used cannabis in the last six months, and less than 13% reported negative side effects. Most of these people reported using cannabis to treat nonmotor Parkinson’s symptoms…
Transplanting dopamine-producing nerve cells grown from monkeys’ own cells back into their brains relieved motor and depression symptoms associated with Parkinson’s disease, a study demonstrated. This approach avoided transplant-associated tissue rejection and supports further research as a treatment option for people…
AbbVie has purchased an exclusive right to acquire Mitokinin, which includes its PINK1 clinical program for the potential treatment of Parkinson’s disease. Under this agreement, Mitokinin will receive an upfront payment and continue to develop its PINK1 compounds by completing an investigational new drug (IND) application and enabling…
A grant from the Michael J. Fox Foundation (MJFF) will help Clene Nanomedicine to advance in development CNM-Au8, its cellular energy-promoting, investigational Parkinson’s treatment. The grant will help to support preclinical studies in patients’ nerve cells and mouse models of the disease, as well as facilitate the launch of a Phase 2 safety and effectiveness…
IMAC Holdings has completed dosing the first group of participants in a Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson’s disease. The group consists of five patients who received a…
Recent Posts
- AAN 2026: VQ-101 reaches the brain, hits target in diverse Parkinson’s patients
- Being a Parkinson’s caregiver meant carrying the weight
- AAN 2026: Parkinson’s cell therapy trial shows sustained benefits
- AAN 2026: Switch to Vyalev stops troublesome dyskinesia in trial
- AAN 2026: Crexont linked to more on time in new Parkinson’s study